Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KT-621, an oral drug, in adults with uncontrolled moderate to severe eosinophilic asthma. This Phase 2b trial aims to understand how well KT-621 works, how safe and tolerable it is, and how the body processes the drug. Participants will be randomly assigned to one of four groups to receive either one of three doses of KT-621 or a matching placebo. Treatment will be given orally, and the study will track changes in lung function and asthma control over 12 weeks. Safety and drug levels in the blood will be monitored through 16 weeks. Throughout the study, participants will attend scheduled visits for lung function tests, asthma symptom questionnaires, and blood tests. Researchers will measure lung function improvement, asthma control, quality of life, treatment side effects, and drug concentration in plasma. The study will last until December 2027, with assessments focused on the 12 to 16-week treatment and monitoring periods.
Actively Recruiting
Researchers are evaluating GB-0895 as an add-on therapy for adolescents and adults with severe asthma that remains uncontrolled despite using inhaled corticosteroids and other asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the effectiveness and safety of GB-0895 in improving asthma outcomes. Participants will receive either GB-0895 or a placebo through subcutaneous injections every six months during the treatment period. The study includes a screening and run-in phase from weeks -5 to 0, a treatment phase lasting 52 weeks, and a follow-up phase lasting from week 52 to week 90. An optional open-label extension allows continued GB-0895 treatment from week 52 through week 142. During the study, participants will undergo various assessments including lung function tests, questionnaires about asthma symptoms and quality of life, and monitoring for asthma exacerbations and adverse events. Researchers will measure outcomes such as the annual rate of asthma exacerbations and changes in lung function over 52 weeks. Safety evaluations will continue throughout treatment and follow-up. The total participation duration may extend up to nearly three years if the optional extension is chosen.
Actively Recruiting
Researchers are evaluating ibuzatrelvir to determine its effectiveness and safety in treating adults and adolescents aged 12 and older who have COVID-19 but are not hospitalized. The study focuses on individuals at high risk of progressing to severe illness. Participants will be randomly assigned to receive either ibuzatrelvir or a placebo, alongside standard care as available locally, with the study lasting approximately six months. Participants will receive either ibuzatrelvir tablets or placebo tablets orally every 12 hours for five days. This is a randomized, double-blind, phase 3 study comparing the investigational drug to placebo. The study allows co-administration of locally available standard treatments. The treatment period is followed by monitoring to assess outcomes related to COVID-19 progression and symptom resolution. During the study, participants will be observed for emergency department visits, hospitalizations, mortality, symptom resolution, and viral load changes over 28 days and up to 24 weeks. Researchers will collect data on medical events, including cardiovascular, renal, and pulmonary complications, as well as Long COVID symptoms. Safety is monitored through adverse event tracking. Overall participation lasts about six months with multiple assessments during this time.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of subcutaneous treatment with lunsekimig compared with placebo in adults aged 40 to 80 years who have inadequately controlled Chronic Obstructive Pulmonary Disease COPD characterized by an eosinophilic phenotype. This Phase 2bPhase 3 study includes participants with a history of COPD, ongoing symptoms despite treatment, and specific lung function and blood eosinophil criteria. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a placebo group. All treatments are given as subcutaneous injections during a 48-week treatment period. The study consists of a screening period up to 4 weeks, followed by the 48-week randomized treatment, and then an approximately 8-week follow-up period, totaling up to 60 weeks of participation. During the study, participants will undergo lung function tests, symptom and quality of life questionnaires, and blood tests to monitor eosinophil counts and drug levels. The main outcome measured is the annualized rate of moderate-to-severe COPD exacerbations over 48 weeks. Additional assessments include changes in lung function, symptom scores, safety events, and antibody development. Safety monitoring continues through the follow-up period after treatment ends.
Actively Recruiting
Researchers are evaluating whether the medicine BI 1291583 can help adults and adolescents aged 12 to under 18 who have bronchiectasis and experience flare-ups, also called exacerbations. This Phase III randomized, double-blind, placebo-controlled study aims to assess the medicines safety, tolerability, and effect on reducing flare-ups in people with this condition. Participants are randomly assigned to one of two groups. One group takes BI 1291583 tablets, and the other takes placebo tablets that look the same but contain no active medicine. They take one tablet daily for up to 76 weeks, or about 1 year and 6 months. The study includes up to 10 in-person visits and around 13 phone calls with study staff during this time. During the study, participants regularly complete a symptom diary on a smartphone about their bronchiectasis. Study doctors monitor participants health, check for flare-ups, and record any unwanted effects. The main outcome measured is the annual rate of pulmonary exacerbations up to week 76, with other assessments including lung function tests and quality of life questionnaires. Participants stay in the study for up to 1 year and 8 months in total.
Actively Recruiting
This research aims to compare two asthma inhalers that use different propellants in people with mild to moderate asthma. The study evaluates whether an investigational inhaler with a new climate-friendly propellant, HFA-152a, works as safely and effectively as inhalers using the existing HFA-134a propellant. This global Phase II study plans to enroll 468 patients in Europe, Latin America, Ukraine, South Africa, and the United Kingdom. Participants will use one of three inhaler treatments in a randomized, double-blind crossover design the investigational CHF5993 pMDI with HFA-152a, CHF5993 pMDI with HFA-134a, or CHF718 pMDI with HFA-134a. Each inhaler is taken as two puffs twice daily. The study compares lung function effects of these inhalers during treatment periods. During the trial, participants will be assessed for lung function through measurements like forced expiratory volume in 1 second FEV1 at baseline and after treatment. Researchers will monitor safety, treatment adherence, and asthma control over the study period. Participants undergo scheduled visits for these evaluations, with the study expected to complete in June 2027.